NDAINHALATIONGAS
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
5/8 — Partial
CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. Approved for burn scars, burns, hypertrophic scar and 12 more indications. First approved in 2025.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARBON DIOXIDE, USP is an inhaled gas approved as a radiographic contrast agent with a mechanism of action in X-ray imaging. The product carries a broad indication portfolio spanning dermatology (burn scars, actinic keratosis), pulmonology (ARDS, resuscitation), neurology (migraine, neonatal encephalopathy), and otolaryngology (vocal cord dysfunction, recurrent respiratory papillomatosis). Its clinical utility appears to extend beyond traditional contrast imaging into therapeutic applications across multiple specialties.
Launch
New launch in LAUNCH lifecycle stage with moderate competitive pressure (30/100) suggests early-stage commercial build-out and team expansion opportunities.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.